Nanovaccines silencing IL-10 production at priming phase for boosting immune responses to melanoma.
Cancer vaccines
Dendritic cells
IL-10
Immunotherapy
Melanoma
Journal
Journal of controlled release : official journal of the Controlled Release Society
ISSN: 1873-4995
Titre abrégé: J Control Release
Pays: Netherlands
ID NLM: 8607908
Informations de publication
Date de publication:
10 10 2021
10 10 2021
Historique:
received:
30
11
2020
revised:
14
08
2021
accepted:
18
08
2021
pubmed:
23
8
2021
medline:
20
11
2021
entrez:
22
8
2021
Statut:
ppublish
Résumé
Despite the significant efforts in developing cancer vaccines, there are still numerous challenges that need to be addressed to ensure their clinical efficacy. Herein, a lymphatic dendritic cell (DC)-targeted artificial nanovaccine mimicking tumor cell membrane (ATM-NV) is developed to boost effector immune response and control immunosuppression simultaneously. The NVs are formulated with lipids, tumor cell membrane proteins, imiquimod (IMQ), and IL-10 siRNA. IL-10 siRNA is incorporated to inhibit the secretion of IL-10, an immunosuppressive cytokine, of maturated DCs upon IMQ. To enhance the DC targeting ability, the nanovaccine surface was non-covalently conjugated with the anti-CD205 antibody. The IMQ and IL-10 siRNA co-loaded, CD205 receptor-targeted artificial tumor membrane NVs (IMQ/siR@ATM-NVs) efficiently migrate to the tumor-draining lymph node and target DCs. Furthermore, immunization with IMQ/siR@ATM-NVs reduces the production of IL-10 and increases T
Identifiants
pubmed: 34419495
pii: S0168-3659(21)00437-5
doi: 10.1016/j.jconrel.2021.08.031
pii:
doi:
Substances chimiques
Cancer Vaccines
0
Interleukin-10
130068-27-8
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
211-223Informations de copyright
Copyright © 2021 Elsevier B.V. All rights reserved.